Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Krystal Biotech Inc
4KBCurrent price
180.6 EUR
0 EUR (0.00%)
Last closed
201.58 USD
Company
www.krystalbio.com
ISIN
US5011471027
Sector
Healthcare
Industry
Biotechnology
Exchange
Frankfurt Exchange
Capitalization
5 791 393 280 USD
Yield for 12 month
+63.93 %
1Y
3Y
5Y
10Y
15Y
4KB
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania. Address: 2100 Wharton Street, Pittsburgh, PA, United States, 15203
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
207.22 USDP/E ratio
51.0329Dividend Yield
–Current Year
+50 699 000 USD
Last Year
–
Current Quarter
+70 284 000 USD
Last Quarter
+45 250 000 USD
Current Year
+42 598 000 USD
Last Year
-4 054 999 USD
Current Quarter
+62 289 000 USD
Last Quarter
+42 831 000 USD
Key Figures 4KB
1 year
3 years
5 years
10 years
EBITDA
8 620 000 USD
Operating Margin TTM
PE Ratio
51.0329
Return On Assets TTM
0.31 %
PEG Ratio
–
Return On Equity TTM
14.2 %
Wall Street Target Price
207.22 USD
Revenue TTM
166 234 000 USD
Book Value
29.22 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
3.95 USD
Diluted Eps TTM
3.95 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
63.73 %
Dividend Analytics 4KB
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 4KB
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation 4KB
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
51.0329
Forward PE
29.0698
Enterprise Value Revenue
31.5186
Price Sales TTM
34.8388
Enterprise Value EBITDA
43.6625
Price Book MRQ
6.9036
Financials 4KB
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators 4KB
For 52 weeks
93.95 USD
219.34 USD
50 Day MA
195.82 USD
Shares Short Prior Month
3 544 246
200 Day MA
159.85 USD
Short Ratio
14.88
Shares Short
3 692 379
Short Percent
16.95 %
BeatStart